What are the most common COVID-19 symptoms in 2026?

Current circulating Omicron subvariants (JN.1 descendants such as NB.1.8.1 'Nimbus' and XFG 'Stratus') typically cause: sore throat, runny nose, fatigue, headache, muscle aches, and mild fever. Loss of smell and taste — once a hallmark of COVID-19 — is significantly less common with Omicron. Some people also experience cough and shortness of breath, though severe lower respiratory disease is less prevalent than with earlier variants in vaccinated individuals.

How long do COVID-19 symptoms last?

For most vaccinated, otherwise-healthy adults with Omicron-era infections, symptoms typically resolve within 5–10 days. Fatigue and cough may linger 1–2 weeks. Symptoms lasting beyond 4 weeks may indicate Long COVID (Post-Acute Sequelae of SARS-CoV-2, or PASC). High-risk individuals and those who are unvaccinated may experience more prolonged illness.

When should I go to the emergency room for COVID-19?

Seek emergency care immediately if you experience any of the CDC's emergency warning signs: trouble breathing or shortness of breath, persistent chest pain or pressure, new confusion or inability to stay awake, or pale, gray, or blue-tinged skin, lips, or nail beds. A persistently low pulse-oximeter reading (for example, at or below about 92%) is also widely used as a prompt to seek urgent care, though it is not itself on the CDC's list. Call your doctor or urgent care for high fever, worsening symptoms, or if you are at high risk for severe illness.

When should I test for COVID-19?

The CDC recommends testing if: you have COVID-19 symptoms; you were exposed to someone with COVID-19 (test 5 days after exposure); you will be in close contact with high-risk individuals; or before attending a large indoor gathering. If symptoms are present, test as soon as possible. A negative rapid antigen test early in illness should be repeated 24–48 hours later, as sensitivity is highest when viral load peaks (typically days 2–4 of illness).

COVID-19 Symptoms by Variant: Omicron, Delta & Original Strain

Name: COVID-19 Symptoms by Variant: Omicron, Delta & Original Strain
Creator: Andy Wilcox
Published: 2024-01-15

Last reviewed: September 14, 2026

Symptoms by Variant

The symptom profile of COVID-19 has changed as the virus evolved. Here is how symptoms compared across the major variants.

COVID-19 Symptoms by Major Variant
Symptom	Original / Alpha	Delta	Omicron (current)
Fever	87.9%	Common	Less common; often low-grade
Cough (dry)	67.7%	Common	Common; often dry
Fatigue	38.1%	Common	Very common
Loss of smell / taste	Not recorded in the February 2020 case series	52.7% (ZOE, vaccinated UK adults)	16.7% (same study) — odds ratio 0.17 (0.16–0.19) vs Delta
Sore throat	13.9%	60.8% (ZOE)	70.5% (ZOE) — odds ratio 1.55 (1.43–1.69) vs Delta
Nasal congestion	4.8%	Moderate	Very common
Headache	13.6%	Common	Very common
Shortness of breath	18.6%	Common; lower lung involvement	Less common; upper respiratory
Muscle / joint aches	14.8%	Common	Common
Nausea / vomiting	5.0%	Less common	Reported more frequently
Diarrhoea	3.7%	Less common	Reported
Hospital admission	13.8% severe, 6.1% critical (of lab-confirmed cases)	2.6% (ZOE, vaccinated)	1.9% (ZOE, vaccinated) — odds ratio 0.75 (0.57–0.98)

Where these numbers come from — and their limits. The original-strain column is the WHO-China Joint Mission report of February 2020, based on 55,924 laboratory-confirmed cases in China. Those are hospital- and clinic-confirmed cases in an untested, unvaccinated population, not a community sample: mild and asymptomatic infections are under-represented, so every figure in that column is higher than the true population rate. The Delta and Omicron figures come from a matched-cohort analysis of the ZOE COVID Study (Menni et al., The Lancet, 2022): 4,990 vaccinated, symptomatic UK adults infected while Delta was >70% prevalent, matched one-to-one on age, sex and vaccine doses with 4,990 infected while Omicron was >70% prevalent. That is a self-reported app cohort of people who chose to log symptoms — informative about the direction and size of the shift, not a census. Cells reading "common" or "moderate" are qualitative descriptions from the wider literature, and we have left them unquantified rather than attach a number no source supports.

Correction, September 14, 2026. An earlier version of this table gave the original-strain column as "83%" fever, "68%" cough and "38%" fatigue with no source named, and described loss of smell or taste as a hallmark of the original strain occurring in 30 to 60 per cent of cases. The figures close to those in the literature are the WHO-China Joint Mission's — 87.9%, 67.7% and 38.1% — and that report does not record loss of smell or taste at all; the symptom was not yet recognised when it was compiled. Every quantified cell in the table now names the study it comes from. Logged on our corrections page.

Note: COVID-19 can present with any combination of these symptoms — or none at all. A positive test is the only reliable way to confirm infection. No symptom pattern identifies which variant someone has. Symptom profiles also vary by vaccination status, prior immunity, and individual health factors.

Current Omicron Symptoms (2025–2026)

Current circulating Omicron subvariants primarily cause upper respiratory illness rather than the lower lung disease seen in earlier variants. Most vaccinated, otherwise-healthy adults experience a cold-like illness. Typical progression:

Days 1–2: Sore throat, runny nose, mild fatigue — often resembles a common cold
Days 2–4: Peak viral load; fever, headache, muscle aches may develop; most contagious period
Days 5–7: Symptoms typically begin to improve; cough and fatigue may linger
Days 7–10: Most people recover fully by this point

High-risk individuals — including the elderly, immunocompromised, and those with underlying conditions — remain at risk for severe disease even with Omicron. If symptoms persist beyond 4 weeks, consider whether you may be experiencing Long COVID. If confirmed positive, contact your doctor promptly to discuss treatment options including Paxlovid, which must be started within 5 days of symptom onset.

Emergency Warning Signs

The CDC identifies the following as emergency warning signs requiring immediate care — call 911 or go to an emergency room without delay:

Trouble breathing or severe shortness of breath at rest
Persistent chest pain or pressure
New confusion or inability to stay awake or alert
Pale, gray, or blue-tinged skin, lips, or nail beds

These four are the emergency warning signs listed by the CDC; the agency notes the list is not exhaustive and to seek care for any severe or concerning symptom. A persistently low pulse-oximeter reading (for example, at or below ~92%) is also widely used as a prompt to seek care — "silent hypoxia" (low oxygen without noticeable breathlessness) is a documented COVID-19 risk — though it is not itself one of the CDC's listed emergency signs.

When to Test

The CDC recommends testing for COVID-19 in these situations:

If you have symptoms — test as soon as possible. Rapid antigen tests are most sensitive days 2–5 after exposure, when viral load peaks.
After a known exposure — test 5 days after exposure, even without symptoms.
Before visiting high-risk individuals — elderly, immunocompromised, or newborns.
Before a large indoor gathering — especially during high community transmission periods.

Testing tip: The CDC notes that a negative rapid antigen test early in illness does not rule out infection. Per CDC guidance, if the first result is negative but symptoms persist or worsen, retesting 24–48 hours later is recommended. PCR tests are more sensitive, especially in early illness.

How Long Are You Contagious?

The CDC's isolation guidance has evolved. For most people:

You are most contagious in the 2 days before symptoms appear through day 5 of illness
The CDC recommends staying home until fever-free (without fever-reducing medication) for 24 hours AND symptoms are improving before resuming normal activities
The CDC advises wearing a mask when around others during days 6–10 of illness
Some immunocompromised individuals may be contagious for longer

Rapid antigen tests can help determine when you are no longer significantly contagious — negative results on consecutive days suggest lower transmission risk. If you have already had COVID-19, note that reinfection is common — test any time you develop cold or flu-like symptoms, even if you had COVID recently.

What CDC Publishes — and What It Deliberately Doesn't

CDC's symptoms page, last updated March 10, 2025, lists eleven possible symptoms in no particular order and attaches no frequency to any of them: fever or chills, cough, shortness of breath, sore throat, congestion or runny nose, new loss of taste or smell, fatigue, muscle or body aches, headache, nausea or vomiting, and diarrhoea. It states plainly that the list "does not include all possible symptoms," that symptoms "may change with new COVID-19 variants," and that they "can vary depending on vaccination status."

That restraint is deliberate and defensible. Producing a reliable national symptom-frequency table requires systematically interviewing a representative sample of infected people, and the United States no longer has a system that does it — COVID-19 stopped being nationally notifiable, most testing moved to at-home antigen kits that generate no report, and the survey instruments built during the emergency have been retired. Rather than publish a frequency it cannot stand behind, CDC publishes a list.

The consequence for a reader is that any site presenting a precise, current, variant-specific symptom percentage is either citing an old study, citing a self-selected app cohort, or making it up. This page names which of the first two each of its numbers is.

How Much COVID-19 Is Around Right Now

Symptoms matter in proportion to the chance you have the infection at all. Three CDC systems still measure that, and they point the same way.

Emergency-department visits. CDC's National Syndromic Surveillance Program publishes the percentage of all US emergency-department visits diagnosed as COVID-19. For the week ending September 5, 2026 it was 0.6%, up from 0.1% in late June — a real late-summer rise, and still fewer than one ED visit in 150. For scale, the same measure peaked at 3.4% in the week ending December 30, 2023, 2.7% in late August 2024, 1.7% in late August 2025, and 1.4% in the first week of January 2025. Each successive peak has been roughly half the last. Peak values are our reading of CDC's published weekly file.

Hospitalisation rates. COVID-NET, CDC's surveillance network for laboratory-confirmed COVID-19 hospitalisations, publishes a cumulative rate per 100,000 population for each surveillance season (October to September). The trajectory is the clearest single series on this site:

2020–21: 520 per 100,000
2021–22: 519
2022–23: 252
2023–24: 200
2024–25: 103
2025–26: 40 through September 5, 2026 (season all but complete)

That is a thirteen-fold fall from the first full pandemic season to the one just ending. It is not a claim that the virus has become intrinsically mild — the same figures are consistent with a population that now has layered immunity from vaccination and repeated infection — but it is the number that belongs beside any question about how worried to be about a sore throat.

Wastewater. CDC's wastewater network reports a viral activity level for each participating treatment plant. Across the 870 sites reporting for the week ending September 5, 2026, the median level was 2.34 — inside CDC's "Very Low" band, which runs up to 2.6 — having risen from 1.00 in mid-July. The distribution is the part a single national number hides: in that same week, 62 sites were in the "Very High" band and 457 in "Very Low." Community-level experience of this late-summer wave is genuinely uneven. The median and the site counts are our calculation from CDC's published site-level file, using the median method CDC states it uses; the activity-level thresholds are CDC's.

What is not known

What fraction of infections are asymptomatic today. The WHO-China Joint Mission judged truly asymptomatic infection "relatively rare" in early 2020, before vaccination and before Omicron. No current US system measures it.
Whether the current lineages differ from each other in symptom profile. Answering that requires linking sequenced infections to symptom reports at scale; as our variants page sets out, US genomic surveillance is now too thin to support it.
A current national case count. COVID-19 is no longer nationally notifiable, so there is no denominator against which to compute a symptom frequency, a hospitalisation rate, or a case-fatality rate for the present day. Our COVID-19 Risk Perspective leaves those cells blank for exactly this reason rather than filling them with a number that would look precise and be wrong.

For how COVID-19's current severity compares with 14 other viruses on the same measures, see the hub's Virus Risk Perspective.

Sources & References

CDC. Symptoms of COVID-19. Page dated March 10, 2025. cdc.gov
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), February 2020 — symptom frequencies among 55,924 laboratory-confirmed cases; 80% mild-to-moderate, 13.8% severe, 6.1% critical. who.int (PDF)
Menni C, et al. "Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study." The Lancet 2022;399:1618–1624. doi:10.1016/S0140-6736(22)00327-0
CDC. NSSP Emergency Department Visits — COVID-19, Flu, RSV, Combined (public dataset; national weekly percentages through the week ending September 5, 2026). data.cdc.gov
CDC. RESP-NET Rates and Clinical Data (COVID-NET cumulative hospitalisation rates per 100,000, by season). data.cdc.gov
CDC. National Wastewater Data for Respiratory Viruses (page dated September 11, 2026; activity-level thresholds and the median method) and the underlying site-level wastewater viral activity dataset. cdc.gov
CDC. Testing for COVID-19. cdc.gov
CDC. Preventing Spread of Respiratory Viruses When You're Sick. cdc.gov
World Health Organization. Coronavirus disease (COVID-19). who.int

Continue Reading

💊

COVID Treatment

Paxlovid, antivirals, dexamethasone, and home care guidance.

Long COVID

Symptoms, risk factors, and the NIH RECOVER Initiative.

Variants

How Omicron and its subvariants differ from prior strains.

Andy Wilcox

Written and researched by Andy Wilcox, an independent researcher not a physician — his work is the product of disciplined primary-source research drawing on 30+ years as a consultant, operating executive, and investor. Nothing here is medical advice.